Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

Hikma Pharmaceuticals KSA, announced the expansion of its strategic partnership with the Saudi Gastroenterology Association ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version ...

Hikma Pharmaceuticals (HIK – Research Report) received a Buy rating and a p2,400.00 price target from Berenberg Bank analyst Victoria Lambert yesterday. The company’s shares closed yesterday ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...